Our key discovery

Brain Bispecific T cell Engager (BRiTE) hitchhiking drug delivery platform

A unique combination of novel T cell engager +
specifically manipulated polyclonal T cells

Benefit at a glance

In robust, preclinical studies and murine models, our BRiTE technology has shown:

• Potential best-in-class efficacy
• High specificity against tumor antigen-expressing glioma cells
• Dose-response heterogeneic efficacy against multiple patient-derived malignant glioma cell lines
• Non-toxicity
• “Bystander” tumor cell lysis
• Efficacy against heterogeneous tumors